These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34849012)

  • 21. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types.
    Wang S; Tong Y; Zong H; Xu X; Crabbe MJC; Wang Y; Zhang X
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
    Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 25. Comprehensive analysis of ZNF family genes in prognosis, immunity, and treatment of esophageal cancer.
    Hong K; Yang Q; Yin H; Wei N; Wang W; Yu B
    BMC Cancer; 2023 Apr; 23(1):301. PubMed ID: 37013470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 27. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer.
    Tuersun H; Liu L; Zhang J; Maimaitizunong R; Tang X; Li H
    Transl Cancer Res; 2023 Sep; 12(9):2319-2335. PubMed ID: 37859733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer.
    Wang X; Wang S; Han Y; Xu M; Li P; Ke M; Teng Z; Huang P; Diao Z; Yan Y; Meng Q; Kuang Y; Zheng W; Liu H; Liu X; Jia B
    Int J Gen Med; 2021; 14():8293-8299. PubMed ID: 34815701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
    Wang L; Ren Z; Yu B; Tang J
    J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
    Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
    Front Surg; 2022; 9():860806. PubMed ID: 35937602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 34. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.
    Cao X; Wu B; Guo S; Zhong W; Zhu S; Zhang Z; Gu L; Li H
    Pathol Oncol Res; 2023; 29():1610976. PubMed ID: 36969562
    [No Abstract]   [Full Text] [Related]  

  • 35. CDKL3 shapes immunosuppressive tumor microenvironment and initiates autophagy in esophageal cancer.
    Bi Y; Liu J; Qin S; Ji F; Zhou C; Yang H; Zhou S
    Front Immunol; 2024; 15():1295011. PubMed ID: 38562942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Immune-Related Ferroptosis Signature in Esophageal Cancer: An Informatics Exploration of Biological Processes Related to the TMEM161B-AS1/hsa-miR-27a-3p/GCH1 Regulatory Network.
    Lu M; Li J; Fan X; Xie F; Fan J; Xiong Y
    Front Genet; 2022; 13():829384. PubMed ID: 35281840
    [No Abstract]   [Full Text] [Related]  

  • 37. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
    Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
    Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
    Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
    Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing a novel necroptosis-related signature to evaluate the prognostic and therapeutic characteristics of esophageal cancer.
    Chen M; Hua T; Yang L; Li C; Xu S; Zhu J; Zhao T
    Am J Transl Res; 2023; 15(8):5425-5445. PubMed ID: 37692951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.